10-K: Elevai Labs Inc. Files 10-K Report for Fiscal Year 2023, Citing Growth and Future Expansion Plans

Elevai Labs Inc. reports increased revenue and outlines strategic growth plans in its annual 10-K filing, while also acknowledging ongoing financial challenges.

Summary

• Elevai Labs Inc., a physician-dispensed skincare company, released its annual report on Form 10-K for the fiscal year ended December 31, 2023.
• The company reported a revenue of $1,712,595 in 2023, a significant increase from $766,277 in 2022.
• Elevai's gross profit also saw a substantial rise, reaching $1,134,580 in 2023 compared to $447,309 in the previous year.
• The company's gross profit margin improved to 66% in 2023 from 58% in 2022.
• However, Elevai experienced a net loss of $4,301,517 in 2023, compared to a net loss of $1,800,268 in 2022.
• The company's operating expenses increased to $4,900,791 in 2023 from $2,238,350 in 2022.
• Elevai is focused on expanding its product lines, increasing production capacity, and growing its international presence.
• The company plans to invest between $1,500,000 and $2,000,000 to double its production capacity in 2025.
• Elevai estimates that developing a single pipeline product will require approximately $250,000 for equipment and an additional $100,000 for testing and launch.
• The company has identified a material weakness in its internal control over financial reporting.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is strong revenue growth and strategic expansion, the significant net loss, material weakness in internal controls, and going concern warning temper the positive aspects. The company faces significant risks and challenges, making the overall sentiment neutral to slightly negative.

Positives

• The company experienced significant revenue growth in 2023.
• Gross profit and gross profit margin improved year-over-year.
• Elevai is actively expanding its international distribution network.
• The company is investing in research and development to create new products.
• Elevai has a strong intellectual property portfolio with patents and trademarks.
• The company has expanded its laboratory space by 721 square feet to increase production capacity.

Negatives

• Elevai reported a net loss of $4,301,517 in 2023, an increase from $1,800,268 in 2022.
• Operating expenses increased significantly in 2023.
• The company has a limited operating history at its current scale.
• Elevai has identified a material weakness in its internal control over financial reporting.
• The company has received notice from Health Canada that its products do not meet the conditions for sale as cosmetics in Canada.
• The company has terminated its white label distribution agreement with DermaPenWorld.

Risks

• The company's revenues and financial results depend significantly on sales of its Elevai Post Treatment E-Series.
• Elevai faces intense competition from companies with greater resources.
• The company may not be able to successfully expand the use of its current product lines or develop new products.
• The company's products could be rendered obsolete by technological or other medical advances.
• The company may encounter difficulties managing its growth.
• The company may be unable to retain its existing sales force and recruit additional people.
• An economic downturn could inhibit consumers from spending their disposable income on aesthetic and skin health products.
• The company's products may cause undesirable side effects that could limit their use.
• The company is subject to risks associated with doing business internationally.
• Potential business combinations could require significant management attention and prove difficult to integrate.
• The company may fail to cost-effectively acquire new client accounts or retain existing clients.
• The company's brand and reputation may be diminished due to real or perceived quality, safety, or environmental impact issues.
• Economic downturns or a change in medical aesthetic consumer preferences could limit demand for the company's products.
• The company may be unable to maintain its company culture or focus on its purpose as it grows.
• The company may lose key personnel or be unable to attract and retain other qualified personnel.
• The company may be unable to accurately forecast revenue and appropriately plan its expenses.
• The company has a limited operating history at its current scale.
• A disruption in the company's operations could have an adverse effect on its business.
• The COVID-19 or another pandemic could have an adverse effect on the company's business.
• The company is at an early stage of product development, and may not develop additional products that can be commercialized.
• The company may incur product liability claims that could harm its business.
• The company's sales force or employees may provide improper or inappropriate advice regarding its products.
• The company has limited clinical validation and testing data.
• The company's products may fail to achieve the broad degree of physician adoption and use or medical aesthetic consumer demand necessary for commercial success.
• The company's products may be expensive to manufacture, and they may not be profitable if the company is unable to control the costs to manufacture them.
• The company's business is based on novel technologies that are inherently expensive, risky and may not be understood by or accepted in the cosmetics marketplace.
• The company may not have sufficient product liability insurance.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a history of net losses, and may not be able to achieve or maintain profitability in the future.
• The company's current growth may not be indicative of its future growth.
• The company will need additional capital to conduct its operations and develop its products and its ability to obtain the necessary funding is uncertain.
• The company depends on its collaborators to help it develop and test its proposed products.
• The company relies on the activities of its non-employee consultants, third-party vendors, and operational contractors.
• The company depends on third-party contract suppliers, packagers, shippers and formulators for all of its required raw materials, bottling and packaging, active ingredients and finished products.
• The company or its third-party vendors may experience network or system failures, or service interruptions, including cybersecurity attacks.
• If the company's third-party suppliers, logistics, and manufacturers do not comply with ethical business practices or with applicable laws and regulations, the company's reputation, business, financial condition, results of operations and prospects could be harmed.
• If the company or its third-party manufacturers or formulators fail to comply with environmental, health and safety laws and regulations, the company could become subject to fines or penalties.
• A recall or suspension of sale of the company's products, or the discovery of serious safety issues with its products could have a significant negative impact on the company.
• Domestic and foreign government regulations and private party actions relating to the marketing and advertising of the company's cosmetics products have and may continue to restrict, inhibit or delay the company's ability to sell its cosmetics products.
• The company may be unsuccessful in its efforts to comply with applicable federal, state and international laws and regulations, which could result in government enforcement actions.
• New regulations could prohibit physicians from dispensing the company's cosmetics products directly.
• Failure to obtain regulatory approvals in foreign jurisdictions would prevent the company from marketing its cosmetics products internationally.
• If the company fails to protect or enforce its intellectual property or confidential proprietary information, others could compete against it more directly.
• The company may not have sufficient product liability insurance, which may leave it vulnerable to future claims it will be unable to satisfy.
• The company's Common Stock price may be volatile, and the value of its Common Stock may decline.
• The company has received letters from Nasdaq stating that it is not in compliance with their continued listing requirements, and it might not be able to regain compliance.
• The company has broad discretion in the use of its existing cash, cash equivalents and may not use them effectively.
• The company has never paid dividends on its common stock, and does not anticipate paying any cash dividends on its common stock in the foreseeable future.
• Sales of a substantial number of shares of the company's common stock in the public market by its existing stockholders could cause its stock price to decline.
• The company's largest stockholders interests may differ from those of its public stockholders.
• Concentration of ownership among the company's executive officers, directors and their affiliates may prevent new investors from influencing significant corporate decisions.
• The company is an emerging growth company, and it cannot be certain if the reduced reporting and disclosure requirements applicable to emerging growth companies will make its Common Stock less attractive to investors.
• Changes in laws or regulations relating to privacy, data protection or the protection or transfer of personal data could adversely affect the company's business.
• The company may be subject to theft, loss, or misuse of personal data about its employees, customers, or other third parties.
• The company or its third-party vendors may experience in the future network or system failures, or service interruptions, including cybersecurity attacks.

Future Outlook

Elevai plans to focus on growing revenue, utilizing clinical validation studies, developing new products, expanding distribution partnerships, and pursuing strategic acquisitions. The company also anticipates the need to expand its production capacity in 2025.

Management Comments

• The company believes it is at the fore of the biotech aesthetic revolution by innovating new cosmetic products at a level of biotech and aesthetics cosmetics research rarely observed in over-the-counter or physician-dispensed cosmetics skincare market.
• The company believes that physicians and their trained staff are the best source of trustworthy skincare information.
• The company believes that its market position in the physician-dispensed channel presents it with the opportunity to increase the market share of its existing products and to launch a range of new products.
• The company believes it has the potential to be one of the most disruptive brands in the physician-dispensed cosmetics skincare market.

Industry Context

Elevai operates in the competitive medical aesthetics skincare market, which is experiencing growth as consumers increasingly seek physician-backed cosmetic solutions. The company's focus on stem cell-derived exosomes positions it within a niche area of the market, leveraging biotechnology to complement medical aesthetic procedures.

Comparison to Industry Standards

• Elevai competes with established brands like SkinCeuticals, SkinMedica, and ZO Skin Health, which have significantly greater resources and market presence.
• Unlike many competitors that rely on synthetic growth factors, Elevai uses ethically sourced human umbilical mesenchymal stem cells (hUMSCs) to produce exosomes.
• The company's focus on the physician-dispensed market aligns with a growing trend of consumers seeking professional advice on cosmetic product selection.
• Elevai's white-label agreements and distribution partnerships are similar to strategies used by other companies to expand market reach.
• The company's reliance on third-party manufacturers and formulators is a common practice in the cosmetics industry, but it also presents risks related to supply chain and quality control.

Related Party Transactions

• The company has ongoing consulting agreements with NorthStrive Companies Inc. and GB Capital Ltd., which are controlled by related parties.
• The company has a consulting agreement with Braeden Litchi, a former director.
• The company has granted stock options to its directors and executive officers.

Stakeholder Impact

• Shareholders face the risk of potential losses due to the company's financial challenges and the volatility of its stock price.
• Employees may be affected by the company's ability to manage growth and retain talent.
• Customers may be impacted by the company's ability to maintain product quality and meet demand.
• Suppliers may be affected by the company's financial stability and ability to pay for raw materials.
• Creditors face the risk of potential losses due to the company's going concern warning.

Next Steps

• The company intends to focus on growing revenue using its existing infrastructure.
• The company intends to utilize clinical validation studies to show the efficacy of its products.
• The company intends to conduct R&D to create new product formulations and bring them to market.
• The company intends to expand its distribution partnerships internationally.
• The company intends to pursue the identification and review of strategic acquisitions to complement its business.

Key Dates

Keywords

skincare, exosomes, cosmetics, medical aesthetics, stem cells, biotechnology, physician-dispensed, topical, hUMSCs, PREx